

研究成果の刊行に関する一覧表（平成25年度分）

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Saito N, Yoshioka N, <u>Abe R</u> , Qiao H, Fujita Y, Hoshina D, Suto A, Kase S, Kitaichi N, Ozaki M, Shimizu H.	Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.	J Allergy Clin Immunol	131	434-441	2013
Qiao H, <u>Abe R</u> , Saito N, Fujita Y, Hayashi-Ujiie I, Wang G, Haga S, Wu C, Ohmiya Y, Ozaki M, Shimizu H.	A method for intravital monitoring of human cells using a far-red luminescent probe in graft-versus-host disease model mice.	J Invest Dermatol	133	841-3	2013
Yoshioka N, Suto A, <u>Abe R</u> , Saito N, Murata J, Hayashi-Ujiie I, Hoshina D, Fujita Y, Shimizu H.	Disturbed balance in three subpopulations of CD4(+)Foxp3(+) regulatory T cells in Stevens-Johnson syndrome and toxic epidermal necrolysis patients.	Clin Immunol	148	89-91	2013

Tanaka A, Nakano M, Tani M, Kira M, <u>Katayama I</u> , Nakagawa J, Tahara K, Koh S, Goto S, Takahashi R.	Adult case of Stevens-Johnson syndrome possibly induced by Chlamydothrix pneumoniae infection with severe involvement of bronchial epithelium resulting in obstructive respiratory disorder.	J Dermatol	40	492-4	2013
山賀 康右, 花房 崇明, 山岡 俊文, 小豆澤 宏明, 片山 一朗, 吉岡 大輔, 戸田 宏一, 澤 芳樹	アスピリンが原因薬と考えられた中毒性表皮壊死症	皮膚病診療	35	1169-1172	2013
Nakajima K, Terao M, Takaishi M, Kataoka S, Goto-Inoue N, Setou M, Horie K, Sakamoto F, Ito M, Azukizawa H, Kitaba S, Murota H, Itami S, <u>Katayama I</u> , Takeda J, Sano S.	Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model	J Invest Dermatol	133	2555-65	2013
Ito T, Hashizume H, Shimauchi T, Funakoshi A, Ito N, Fukamizu H, Takigawa M, <u>Tokura Y</u> :	CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase.	J Dermatol Sci	69	140-147	2013
Hiroike M, Sakabe J, Kobayashi M, Shimauchi T, Ito T, Hirakawa S, Inoh A, <u>Tokura Y</u> :	Acicular, but not globular, titanium dioxide nanoparticles stimulate keratinocytes to produce pro-inflammatory cytokines.	J Dermatol	40	357-362	2013

Umayahara T, Shimauchi T, <u>Fujiyama T</u> , Ito T, Hirakawa S, <u>Tokura Y</u> :	Paediatric acute generalized exanthematous pustulosis induced by paracetamol with high serum levels of interleukin-8 and -22: a case report.	Acta Derm Venereol	93	362-363	2013
<u>Fujiyama T</u> , <u>Tokura Y</u> :	Clinical and histopathological differential diagnosis of eosinophilic pustular folliculitis.	J Dermatol	40	419-423	2013
Sakabe J, Yamamoto M, Hirakawa S, Motoyama A, Ohta I, Tatsuno K, Ito T, Kabashima K, Hibino T, <u>Tokura Y</u> :	Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes.	J Biol Chem	288	17179-17189	2013
Mori T, Kabashima K, Fukamachi S, Kuroda E, Sakabe J, Kobayashi M, Nakajima S, Nakano K, Tanaka Y, Matsushita S, Nakamura M, <u>Tokura Y</u> :	D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells.	J Dermatol Sci	71	37-44	2013
Shimauchi T, Hirakawa S, Suzuki T, Yasuma A, Majima Y, Tatsuno K, Yagi H, Ito T, <u>Tokura Y</u> :	Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis.	J Dermatol	40	805-812	2013
Ito T, Fujiyama T, Hashizume H, <u>Tokura Y</u> :	Antihistaminic drug olopatadine downmodulates T cell chemotaxis toward CXCL10 by reducing CXCR3 expression, F-actin polymerization and calcium influx in patients with alopecia areata.	J Dermatol Sci	72	68-71	2013

Yamaguchi H, Kabashima-Kubo R, Bito T, Sakabe JI, Shima uchi T, Ito T, Hirakawa S, Hirasawa N, Ogasawara K, Tokura Y:	High frequencies of positive nickel/cobalt patch tests and high sweat nickel concentration in patients with intrinsic atopic dermatitis.	J Dermatol Sci	72	240-245	2013
Shiraishi N, Nomura T, Tanizaki H, Nakajima S, Narumiya S, Miyachi Y, Tokura Y, Kabashima K:	Prostaglandin E2-EP3 Axis in Fine-tuning Excessive Skin Inflammation by Restricting Dendritic Cell Functions.	PLoS ONE	8	e69599	2013
Sugita K, Nomura T, Ikenouchi-Sugita A, Sakabe JI, Nakahigashi K, Kuroda E, Uematsu U, Nakamura J, Akira S, Nakamura M, Narumiya S, Miyachi Y, Tokura Y, Kabashima K:	Prostaglandin E2 is critical for the development of niacin-deficiency-induced photosensitivity via ROS production.	Sci Rep	3	2973	2013
Sawada Y, Nakamura M, Bito T, Sakabe JI, Kabashima-Kubo R, Hino R, Kobayashi M, Tokura Y:	Decreased expression of acetylcholine esterase in cholinergic urticaria with hypohidrosis or anhidrosis.	J Invest Dermatol	134	276-279	2014
Fujiyama T, Kawakami C, Suigita K, Kubo-Kabashima R, Sawada Y, Hino R, Nakamura M, Shimauchi T, Ito T, Kabashima K, Hashizume H, Tokura Y:	Increased frequencies of Th17 cells in drug eruptions.	J Dermatol Sci	73	85-88	2014

Sakabe J-I, Umayahara T, Hiroike M, Shimauchi T, Ito T, <u>Tokura Y:</u>	Calcipotriol increases hCAP18 mRNA expression but inhibits extracellular LL37 peptide production in IL-17/IL-22-stimulated normal human epidermal keratinocytes.	Acta Derm Venereol	94	512-516	2014
Suzuki T, Hirakawa S, Shimauchi T, Ito T, Sakabe J, Detmar M, <u>Tokura Y:</u>	VEGF-A promotes IL-17A-producing $\gamma\delta$ T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells.	J Dermatol Sci	74	116-124	2014
Yoshiki R, Kabashima K, Honda T, Nakamizo S, Sawada Y, Sugita K, Yoshioka H, Ohmori S, Malissen B, <u>Tokura Y,</u> Nakamura M:	IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing $\gamma\delta$ T cells.	J Invest Dermatol	134	1912-1921	2014
戸倉新樹 :	光線過敏型薬疹の原因薬剤と診断.	日本医師会雑誌	142	522-526	2013
Kono M, Sugiura K, Suganuma M, Hayashi M, Takama H, Suzuki T, Matsunaga K, Tomita Y, <u>Akiyama M.</u>	Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease.	Hum Mol Genet	22	3524-33	2013
Sugiura K, Muto M, <u>Akiyama M.</u>	CARD14 c.526G>C (p.Asp176His) Is a Significant Risk Factor for Generalized Pustular Psoriasis with Psoriasis Vulgaris in the Japanese Cohort.	J Invest Dermatol	134	1755-1757	2014
Shibata A, Ogawa Y, Sugiura K, Muro Y, Abe R, Suzuki T, <u>Akiyama M</u>	High survival rate of harlequin ichthyosis in Japan.	J Am Acad Dermatol	70	387-8	2014
Yasuda K, Sugiura K, Takeichi T, Ogawa Y, Muro Y, <u>Akiyama M.</u>	Nuclear envelope localization of Ran-binding protein 2 and Ran-GTPase-activating protein 1 in psoriatic epidermal keratinocytes.	Exp Dermatol	23	119-24	2014

Tanahashi K, Sugiura K, Asagoe K, Aoyama Y, Iwatsuki K, Akiyama M	Novel TGM1 Missense Mutation p.Arg727Gln in a Case of Self-healing Collodion Baby.	Acta Derm Venereol	94	589-590	2014
Sugiura K, Koga H, Ishikawa R, Matsumoto T, Matsubara M, Hagiwara R, Muro Y, Hashimoto T, Akiyama M.	Paraneoplastic pemphigus with anti-laminin-332 autoantibodies in a patient with follicular dendritic cell sarcoma.	JAMA Dermatol	149	111-113	2013
Nomura Y, Nomura T, Sakai K, Sasaki K, Ohguchi Y, Mizuno O, Hata H, Aoyagi S, Abe R, Itaya Y, Akiyama M, Shimizu H	A novel splice site mutation in NCSTN underlies a Japanese family with hidradenitis suppurativa.	Br J Dermatol	168	206-209	2013
Takeichi T, Sugiura K, Matsuda K, Kono M, Akiyama M.	Novel ABCA12 splice site deletion mutation and ABCA12 mRNA analysis of pulled hair samples in harlequin ichthyosis.	J Dermatol Sci	69	259-261	2013
Sugiura K, Sugiura N, Yagi T, Iguchi M, Ohno H, Miyazaki Y, Akiyama M.	Cryptococcal cellulitis in a patient with bullous pemphigoid.	Acta Dermato-Venereol	93	187-188	2013
Tanahashi K, Sugiura K, Takeichi T, Takama H, Shinkuma S, Shimizu H, Akiyama M.	Prevalent founder mutation c.736T>A of LIPH in autosomal recessive woolly hair of Japanese leads to variable severity of hypotrichosis in adulthood.	J Eur Acad Dermatol Venereol	27	1182-1184	2013
Kono M, Akiyama M, Suganuma M, Tomita Y	Sanchez-Valle A. Dyschromatosis symmetrica hereditaria by ADAR1 mutations and viral encephalitis: a hidden link?	Int J Dermatol	52	1582-4	2013

Takeichi T, Sugiura K, Arai H, Ishii K, Kono M, <u>Akiyama M</u>	Sporadic VACTERL association in a Japanese family with Sjögren-Larsson syndrome.	Acta Dermato-Venereol	93	579-580	2013
Sugiura K, Matsumoto T, Muro Y, <u>Akiyama M.</u>	Unilaterally dominant eosinophilic fasciitis after influenza vaccination.	J Am Acad Dermatol	69	e269-70	2013
Matsumoto T, Yokota K, Sawada M, Sakakibara A, Shibata S, Yasue S, Tomita Y, Yatsuya H, <u>Akiyama M</u>	Postoperative DAV-IFN- β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.	J Eur Acad Dermatol Venereol	27	1514-20	2013
Shibata A, Sugiura K, Kimura U, Takamori K, <u>Akiyama M</u>	A novel ATP2C1 early truncation mutation suggests haploinsufficiency as a pathogenic mechanism in a patient with Hailey-Hailey disease.	Acta Dermato-Venereol	93	719-720	2013
Shinkuma S, Nishie W, Jacyk WK, Natsuga K, Ujii H, Nakamura H, <u>Akiyama M,</u> Shimizu H.	A novel keratin 5 mutation in an African family with epidermolysis bullosa simplex indicates the importance of the amino acid located at the boundary site between the H1 and coil 1A domains.	Acta Dermato-Venereol	93	585-587	2013
Shimizu Y, Sugiura K, Aoyama Y, Ogawa Y, Hitomi K, Iwatsuki K, <u>Akiyama M.</u>	Novel ABCA12 missense mutation p.Phe2144Ser underlies congenital ichthyosiform erythroderma.	J Dermatol	40	581-582	2013
Sugiura K, Teranishi M, Matsumoto Y, <u>Akiyama M</u>	Clouston syndrome with heterozygous GJB6 mutation p.Ala88Val and GJB2 variant p.Val27Ile revealing mild sensorineural hearing loss and photophobia.	JAMA Dermatol	149	1350-1351	2013
Sugiura K, Tanahashi K, Muro Y, <u>Akiyama M</u>	Cutaneous lupus mucinosus successfully treated with systemic corticosteroid and systemic tacrolimus combination therapy.	J Am Acad Dermatol	69	e200-202	2013
Nin-Asai R, Sawada M, Matsumoto T, Saito S, Yokota K, <u>Akiyama M.</u>	Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.	J Dermatol	41	178-9	2014

小豆澤 宏明	【重症薬疹の診断と治療】 薬疹におけるリンパ球刺激試験でとらえる薬剤特異的T細胞	臨床免疫・アレルギー科	59	438-444	2013
小豆澤 宏明	薬疹を診る-注意点とその対応】 最近の薬疹 注意すべき薬剤とその臨床症状	日本医師会雑誌	142	503-507	2013
Nakajima K, Terao M, Takaishi M, Kataoka S, Goto-Inoue N, Setou M, Horie K, Sakamoto F, Ito M, <u>Azukizawa H</u> , Kitaba S, Murota H, Itami S, <u>Katayama I</u> , Takeda J, Sano S.	Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model.	J Invest Dermatol	133	2555-65	2013
Hirobe S, <u>Azukizawa H</u> , Matsuo K, Zhai Y, Quan YS, Kamiyama F, Suzuki H, <u>Katayama I</u> , Okada N, Nakagawa S	Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device.	Pharm Res	30	2664-74	2013

IV. 研究成果の刊行物・別刷（抜粋）

Correspondence

Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome

DOI: 10.1111/j.1365-2133.2012.10921.x

MADAM, Drug-induced hypersensitivity syndrome (DIHS),¹ also known as drug rash with eosinophilia and systemic symptoms (DRESS),² has been established as a clinical entity in severe cutaneous adverse drug reactions. DIHS is characterized by the limited number of causative drugs, late onset, clinical similarity to infectious mononucleosis-like syndrome and prolonged clinical course due to relapse.¹

Granulysin is a cytotoxic molecule produced against virus-infected cells, tumour cells, transplant cells, bacteria, fungi and parasites.³ It plays an important role in the host defence against pathogens. A recent paper reported that granulysin is highly expressed in blisters of two other severe cutaneous adverse drug reactions: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).⁴ In addition, we found that serum granulysin is more elevated in patients with early-stage SJS/TEN than in those with ordinary drug-induced skin reactions (ODSRs).⁵

This paper investigates the serum granulysin level of patients with DIHS. We assembled serum samples of patients with DIHS and analysed the correlation between granulysin concentrations with clinical manifestations and disease courses.

Sera of 15 patients with DIHS (10 men and five women; mean \pm SD age 55.4 ± 19.9 years) were obtained from multiple institutions. All the patients had actively progressing reactions meeting the criteria for DIHS, as previously defined.¹ The disease onset (day 1) was defined as when the skin eruption appeared. Sera of patients with ODSRs ($n = 24$) and healthy controls ($n = 31$) were also obtained. ODSRs included maculopapular-type and erythema multiforme-type reactions. The granulysin concentrations of the serum samples were measured with an enzyme-linked immunosorbent assay as previously described.⁶ In brief, serum samples were incubated on plates coated with RB1 antibody (MBL, Nagoya, Japan) and then reacted with biotinylated RC8 antibody (MBL). We performed assays in blind of the clinical features.

In serum samples taken from day 1 to day 10 ($n = 9$), eight samples (89%) showed elevated serum granulysin levels, over 10 ng mL^{-1} (mean \pm SD $21.9 \pm 12 \text{ ng mL}^{-1}$). In serum samples taken from day 11 to day 20 ($n = 11$), we detected elevated serum granulysin levels in seven (64%; mean \pm SD $16.1 \pm 14.8 \text{ ng mL}^{-1}$). Serum granulysin levels decreased

gradually after day 21 ($n = 20$) [six elevated (30%; mean \pm SD $7.6 \pm 3.4 \text{ ng mL}^{-1}$] (Fig. 1). By day 20, the skin eruptions of all the patients with DIHS had disappeared. As we reported previously, no increase of granulysin level was detected in 31 healthy control subjects (mean \pm SD $1.6 \pm 0.6 \text{ ng mL}^{-1}$) and elevated granulysin was detected in only one of 24 patients with ODSRs (4%; mean \pm SD $3.5 \pm 3.4 \text{ ng mL}^{-1}$).⁵

To distinguish DIHS from ODSRs, the following clinical information is helpful: limited causative drugs; late onset after medication; manifestations similar to infectious mononucleosis such as fever, lymphadenopathy, hepatitis and haematological abnormalities. However, because of the diversity of ODSRs and similarity to viral exanthema, DIHS sometimes poses a diagnostic challenge. In addition, some patients have multiple organ failure. Therefore, early diagnosis and appropriate treatment is essential.

Unique mechanisms have been implicated in DIHS development, including detoxification defects leading to reactive metabolite formation and subsequent immunological reactions,⁷




Fig 1. Granulysin levels of healthy controls, and of patients with ordinary drug-induced skin reactions (ODSRs) and drug-induced hypersensitivity syndrome (DIHS) at different stages of the disease. In patients with DIHS, we examined the concentration of granulysin for three periods: day 1–10, day 11–20, and day 21 onwards. The granulysin level was elevated from day 1 to 20, compared with levels for ODSRs and normal controls (* $P < 0.01$).

and reactivation of human herpesvirus (HHV).⁸ In addition, it is increasingly apparent that there is a genetic predisposition to adverse drug reactions. Human leucocyte antigen-related genes have been identified as predictors of DIHS.⁹

In particular, the observation that HHV reactivation occurs during the acute phase of DIHS has led to suggestions of a pathogenic link. Shiohara *et al.*⁸ identified early reactivation of HHV6 and Epstein–Barr virus (EBV), with later involvement of HHV7 and cytomegalovirus. The resulting expansion of virus-specific T cells might mediate the clinical disease. A recent paper showed that cutaneous and visceral symptoms of DIHS/DRESS are mediated by activated CD8+ T lymphocytes, which are directed against herpesviruses such as EBV.¹⁰

Granulysin exhibits potent cytotoxicity against a broad panel of microbial targets, including tumour cells, transplant cells, bacteria, fungi and parasites, damaging negatively charged cell membranes because of its positive charge.³ Granulysin plays important roles in the host defence against pathogens and induces apoptosis of the target cells in a mechanism involving caspases and other pathways.³ In the present study, we showed that granulysin levels in sera were significantly elevated in patients with DIHS compared with those with ODSRs. It is suggested that, in DIHS, activation of virus-specific cytotoxic T cells resulted in granulysin release in circulating blood. In contrast, granulysin was identified as the most highly expressed cytotoxic molecule in blisters of SJS/TEN resulting in massive keratinocyte apoptosis,⁴ and we revealed that serum granulysin increased in early stage of SJS/TEN.⁵ We speculated that granulysin is involved in SJS/TEN pathogenesis, inducing keratinocyte death in the early stage of these diseases, whereas serum granulysin in DIHS might be released against virus-infected cells. This speculation is consistent with the present data that show the duration of DIHS manifestation to coincide with the timing of elevated serum granulysin levels. Recently we developed a rapid immunochromatographic test to detect high serum granulysin level in 15 min.⁶ We expect that monitoring of serum granulysin by this rapid test might contribute to the early diagnosis of DIHS as well as of SJS/TEN. In conclusion, serum granulysin might help early diagnosis and predict disease prognosis.

Department of Dermatology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan
Correspondence: Riichiro Abe.
E-mail: aberi@med.hokudai.ac.jp

N. SAITO
R. ABE
N. YOSHIOKA
J. MURATA
Y. FUJITA
H. SHIMIZU

References

- Tohyama M, Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. *J Dermatol* 2011; **38**:222–8.
- Kardaun SH, Sidoroff A, Valeyrie-Allanore L *et al.* Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? *Br J Dermatol* 2007; **156**:609–11.
- Kaspar AA, Okada S, Kumar J *et al.* A distinct pathway of cell-mediated apoptosis initiated by granulysin. *J Immunol* 2001; **167**:350–6.
- Chung WH, Hung SI, Yang JY *et al.* Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. *Nat Med* 2008; **14**:1343–50.
- Abe R, Yoshioka N, Murata J *et al.* Granulysin as a marker for early diagnosis of the Stevens–Johnson syndrome. *Ann Intern Med* 2009; **151**:514–15.
- Fujita Y, Yoshioka N, Abe R *et al.* Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens–Johnson syndrome and toxic epidermal necrolysis. *J Am Acad Dermatol* 2011; **65**:65–8.
- Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. *In vitro* assessment of risk. *J Clin Invest* 1988; **82**:1826–32.
- Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. *Allergol Int* 2006; **55**:1–8.
- Ozeki T, Mushiroda T, Yowang A *et al.* Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. *Hum Mol Genet* 2011; **20**:1034–41.
- Picard D, Janela B, Descamps V *et al.* Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. *Sci Transl Med* 2010; **2**:46ra62.

Funding sources: none.

Conflicts of interest: none declared.

Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients

Nao Saito, MD,^{a*} Naoya Yoshioka, PhD,^{a*} Riichiro Abe, MD, PhD,^a Hongjiang Qiao, MD, PhD,^a Yasuyuki Fujita, MD, PhD,^a Daichi Hoshina, MD,^a Asuka Suto, DVM,^a Satoru Kase, MD, PhD,^b Nobuyoshi Kitaichi, MD, PhD,^b Michitaka Ozaki, MD, PhD,^c and Hiroshi Shimizu, MD, PhD^a Sapporo, Japan

Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening cutaneous reactions caused by drugs or infections and exhibiting widespread epidermal necrosis. Currently, there is no animal model that reproduces SJS/TEN symptoms.

Objective: We sought to develop a novel mouse model of SJS/TEN by using PBMCs and skin from patients who had recovered from SJS/TEN.

Methods: For our mouse model, patients' PBMCs were injected intravenously into immunocompromised NOD/Shi-*scid*, IL-2R γ^{null} (NOG) mice, followed by oral administration of a causative drug. Subsequently, to replace human skin, unaffected skin specimens obtained from patients who had recovered from SJS/TEN were grafted onto NOG mice, after which patient-derived PBMCs and the causative drug were applied.

Results: Mice injected with PBMCs from patients with SJS/TEN and given the causative drug showed marked conjunctival congestion and numerous cell death of conjunctival epithelium, whereas there were no symptoms in mice injected with PBMCs from patients with ordinary drug skin reactions. CD8⁺ T lymphocyte-depleted PBMCs from patients with SJS/TEN did not elicit these symptoms. In addition, skin-grafted mice showed darkening of the skin-grafted areas. Cleaved caspase-3 staining showed that dead keratinocytes were more numerous in the skin-grafted mice than in the healthy control animals.

Conclusion: We have established a novel human-oriented SJS/TEN mouse model and proved the importance of CD8⁺ T lymphocytes in SJS/TEN pathogenesis. The mouse model promises to promote diagnostic and therapeutic approaches. (*J Allergy Clin Immunol* 2013;131:434-41.)

Key words: Stevens-Johnson syndrome, toxic epidermal necrolysis, animal models

From the Departments of ^aDermatology, ^bOphthalmology, and ^cMolecular Surgery, Hokkaido University Graduate School of Medicine.

*These authors contributed equally to this work.

Supported in part by Health and Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare of Japan (Research on Allergic Diseases and Immunology; H21-Meneki-Wakate-009 to R.A.) and by the Akiyama Life Science Foundation (to R.A.).

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication February 27, 2012; revised July 28, 2012; accepted for publication September 13, 2012.

Available online October 27, 2012.

Corresponding authors: Riichiro Abe, MD, PhD, Department of Dermatology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan. E-mail: aberi@med.hokudai.ac.jp. Or: Hiroshi Shimizu, MD, PhD, Department of Dermatology, Hokkaido University Graduate School of Medicine, N15 W7, Sapporo 060-8638, Japan. E-mail: shimizu@med.hokudai.ac.jp.

0091-6749/\$36.00

© 2012 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaci.2012.09.014>

Abbreviations used

APC:	Antigen-presenting cell
CTL:	Cytolytic T lymphocyte
DC:	Dendritic cell
FITC:	Fluorescein isothiocyanate
GVHD:	Graft-versus-host disease
GVHR:	Graft-versus-host reaction
NK:	Natural killer
NOG:	NOD/Shi- <i>scid</i> , IL-2R γ^{null}
ODSR:	Ordinary drug skin reaction
PE:	Phycocerythrin
sFasL:	Soluble Fas ligand
SJS:	Stevens-Johnson syndrome
TEN:	Toxic epidermal necrolysis
TUNEL:	Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening mucocutaneous reactions characterized by extensive detachment of the epidermis.¹ They are considered part of the same spectrum of diseases but with different severities. Patients with SJS have skin detachment on less than 10% of the body surface area, whereas patients with TEN have more extensive lesions.² The overall incidences of SJS and TEN have been estimated at 1 to 6 cases per million person-years and 0.4 to 1.2 cases per million person-years, respectively. The mortality associated with TEN is 25%. The eruptions are initially distributed on the face, trunk, and extremities but can rapidly extend to the whole body within just a few hours. Mucous membrane involvement is observed in approximately 90% of cases. Approximately 85% of patients have conjunctival lesions. Ocular complications include chronic conjunctivitis, conjunctival scarring, corneal vascularization, and corneal damage, which can lead to blindness. Ocular morbidity and visual loss can be caused by acute corneal complications, and progressive conjunctival scarring is also significantly associated with subsequent loss of vision.³ Several treatments have been attempted, including high-dose corticosteroids, intravenous immunoglobulin, and plasmapheresis; however, some cases are resistant to these therapies.⁴ In some cases only supportive therapy is applied out of concern over the immunosuppressive effect of these treatments.⁵

The pathologic mechanisms of SJS/TEN are not fully known.⁶ Several mediators to induce SJS/TEN have been proposed, such as Fas ligand,⁷ soluble Fas ligand (sFasL),⁸ perforin, granzyme B,⁹ and granulysin.^{10,11} These mechanisms can induce massive epithelial cell death. Nevertheless, no one has been able to explain why these systemic "cell-death mediators" affect skin

exclusively and result in widespread mucocutaneous erosions without dysfunction of other organs. Indeed, serum sFasL levels are increased not only in patients with SJS/TEN but also in those with viral infections¹² and graft-versus-host disease (GVHD).¹³

Because there is only 1 available animal model, basic research on SJS/TEN is still quite preliminary. Azukizawa et al^{14,15} generated transgenic mice that express the foreign antigen ovalbumin only on keratinocytes. Injections of ovalbumin-specific cytotoxic T cells induced erosive skin manifestations and numerous apoptotic keratinocytes. Although this model showed widespread erosions and partially elucidated the pathomechanisms of skin lesions in patients with SJS/TEN, the model did not reproduce the drug-specific immune reactions that occur in the patients' blood cells and skin component cells. A more precise drug-triggered SJS/TEN mouse model is urgently required for a more complete understanding of SJS/TEN pathomechanisms and preclinical studies for novel therapeutic strategies.

In light of this, we aimed to develop a relevant animal model of SJS/TEN using patients' tissue samples to reproduce a reaction identical to that of SJS/TEN. Using immunocompromised mice, we successfully evoked the same reactions between the causative drug and human immune cells.

METHODS

Patients' samples

A total of 6 patients with SJS/TEN participated in this study (the patient information is detailed in the Table E1 in this article's Online Repository at www.jacionline.org). The causative drugs were acetaminophen in 4 patients, amoxicillin in 1 patient, and phenytoin in 1 patient. Blood samples were taken from patients with SJS/TEN at least 6 months to 3 years after complete remission of symptoms. Skin biopsy specimens were taken at least 1 year after complete remission of symptoms. The patients had received no systemic glucocorticoids before the study. Ordinary drug skin reactions (ODSRs) in our experiments included the maculopapular type and excluded other adverse drug reactions, such as drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms and acute generalized exanthematous pustulosis. Samples were obtained from Hokkaido University Hospital. The collection of samples was approved by the local ethics committee and the institutional review board of Hokkaido University, and each patient provided written informed consent.

Mice

Immunocompromised NOD/Shi-*scid*, IL-2R γ^{null} (NOG) mice at 6 to 7 weeks of age were purchased from the Central Institute for Experimental Animals (Tokyo, Japan). With human PBMCs, NOG mice have been used as models of human disease, such as HIV infection.¹⁶ All the animal experiments were performed under the approval of the ethics committee for animal studies of Hokkaido University.

Analysis of graft-versus-host reactions

A graft-versus-host reaction (GVHR) was induced by means of intravenous injection of human PBMCs. Whole PBMCs (1×10^7) were obtained from healthy control subjects, suspended in 0.1 mL of PBS, and then injected intravenously into NOG mice. Skin, ocular, and mucous manifestations were observed. Body weight was monitored. Peripheral blood and splenocytes were analyzed by using flow cytometry to detect human cells. Skin and ocular lesions were investigated histopathologically.

ELISpot IFN- γ assay

PBMCs were prepared from patients' blood and isolated by using Ficoll-Isopaque (Pharmacia Fine Chemicals, Piscataway, NJ) density

gradient centrifugation. Mouse peripheral cells and splenocytes were also isolated. The number of IFN- γ -producing cells was determined by using an ELISpot assay kit (Human IFN- γ ELISpot PVDF-Enzymatic; Diaclone, Besancon, France). Ninety-six-well nitrocellulose plates were washed 3 times with PBS before use, and PBMCs (2×10^5 in 100 μL) were incubated overnight with causative drugs in RPMI-1640 medium supplemented with 2 mmol/L L-glutamine, 25 mmol/L HEPES buffer, and 10% heat-inactivated autologous serum. Plates were washed 3 times with PBS, incubated for 2 hours with a biotinylated anti-IFN- γ antibody, and extensively washed. IFN- γ spot-forming cells were developed by using streptavidin-alkaline phosphatase, incubated for 2 hours, and washed before addition of the substrate (5-bromo-4-chloro-3-indolyl-phosphate). The number of spots was counted by using a dissecting microscope (SMZ1500; Nikon, Tokyo, Japan), and the frequency of IFN- γ lymphocytes was defined as the number of spots in 2×10^5 mononuclear cells. The drug-specific reactions between antigen-presenting cells (APCs) and antigen-specific T cells resulted in production of IFN- γ from drug-specific lymphocytes (ie, the IFN- γ -producing T cells are antigen-specific [causative drug-specific] T cells). Using the ELISpot assay, we detected causative drug-specific T cells.

SJS/TEN mouse model using patients' PBMCs

PBMCs were obtained from patients who had recovered from SJS/TEN. In some experiments isolated PBMCs were restimulated with causative drugs in completed RPMI media for 6 days. In other experiments CD4⁺ or CD8⁺ cells in PBMCs were depleted by using a magnet-activated cell sorter (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). PBMCs (2×10^6) were injected intravenously into the NOG mice, followed by oral administration of the causative drugs (acetaminophen, amoxicillin, or phenytoin, 100 μL). The dosage used in the model mice was based on milligrams per kilogram of body weight converted from the adult human normal dose. We administered the drug to the mice once daily. In addition, we confirmed that the dosage was under the median lethal dose in mice. Drug dosage was estimated by dose conversion by body weight. We checked for any changes of the skin, eyes, and mucosa, such as skin color or mucous hemorrhage. Peripheral blood and splenocytes were analyzed by using flow cytometry to detect human cells. Skin, ocular, and liver lesions were investigated by means of histopathologic examination and immunohistochemical staining.

Flow cytometric analysis

Cells were stained with the following antibodies: phycoerythrin (PE)-conjugated mouse CD45, fluorescein isothiocyanate (FITC)-conjugated human CD45, peridinin-chlorophyll-protein complex-conjugated human CD3, FITC-conjugated human CD4, PE-conjugated human CD8, or PE-Cy7-conjugated human CD56 (BD Biosciences, San Jose, Calif). Analysis was performed by using a FACSAria with BD FACSDiva software (BD Biosciences).

Immunohistochemistry

Immunostaining of ocular, skin, and liver tissues was performed with antibodies to cleaved caspase-3 (Cell Signaling Technology, Beverly, Mass) and human CD4 and CD8 (BD Biosciences). FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, Pa) and TRITC-conjugated rabbit anti-rat IgG (Sigma-Aldrich, St Louis, Mo) were used as secondary antibodies. The nuclei were counterstained with propidium iodide. Fluorescence staining was detected with a confocal laser scanning fluorescence microscope (Fluoview FV1000; Olympus, Tokyo, Japan). We counted the number of stained cells from 5 separate fields, and the average was shown. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) is a method for detecting apoptotic cells with DNA fragmentation by labeling the terminal end of nucleic acids. The TUNEL assay was performed according to the manufacturer's protocol (Takara Bio, Shiga, Japan).




FIG 1. Development of SJS/TEN model mice by using PBMCs of patients who had recovered from SJS/TEN. **A**, Scheme of model mice development. PBMCs were obtained from patients who had recovered from SJS/TEN. These PBMCs (2×10^6) were injected intravenously into NOG mice, followed by oral administration of the causative drugs. **B**, Causative drug-specific cells were detected by using the human IFN- γ ELISpot. When the causative drug was added to cultured PBMCs of patients who had recovered from SJS/TEN (patient 2), causative drug-specific lymphocytes were detected (30 spots per 2×10^5 cells). After 2 stimulations of the causative drug (restimulation), the number of drug-specific lymphocytes increased (90 spots per 2×10^5 cells). Samples from patients 1 to 6 with SJS/TEN were analyzed, and representative data (patient 2) are shown. *i.v.*, Intravenous; *p.o.*, by mouth.

Measurement of human granulysin and human/mouse sFasL

Human granulysin and human/mouse sFasL in supernatants of PBMCs or sera from SJS/TEN model mice were measured by using ELISA. Human granulysin ELISA (BML, Tokyo, Japan) was performed as previously reported.¹¹ Human/mouse sFasL levels were measured by using an ELISA kit from R&D Systems (Minneapolis, Minn).

SJS/TEN mouse model using patients' PBMCs and skin

Full-thickness skin grafts from healthy control subjects or patients who had recovered from SJS/TEN or an ODSR were transplanted onto the NOG mice. After skin engraftment (approximately 12 days after transplantation), causative drug-stimulated PBMCs (2×10^6) from the same patient were injected intravenously into these mice, followed by oral administration of the causative drug. Changes in skin graft appearance, such as darkening, were observed. The skin grafts were investigated histopathologically.

RESULTS

Development of SJS/TEN mouse model using PBMCs from patients who had recovered from SJS/TEN

To develop the SJS/TEN mouse model, we used PBMCs from patients who had recovered from SJS/TEN. The PBMCs were injected intravenously into immunocompromised mice, followed by oral administration of the causative drug (Fig 1, A). There are several reports on the existence of drug-specific lymphocytes in patients who had recovered from drug allergies, and these lymphocytes were restimulated by the causative drug *in vitro*.^{17,18} Therefore if lymphocytes that specifically reacted to the drug remained in the peripheral blood, these lymphocytes would be restimulated by the causative drug, and identical immunologic reactions to those of patients with active SJS/TEN would occur in the mice.

First, we confirmed the presence of causative drug-specific lymphocytes in peripheral blood. ELISpot analysis of human IFN- γ was conducted to detect antigen-specific human cells. When the causative drug was added to cultured PBMCs from

patients who had recovered from SJS/TEN, causative drug-specific lymphocytes were detected (Fig 1, B). After *in vitro* restimulation of the causative drug, the number of drug-specific lymphocytes increased. To exclude the possibility of *in vitro* priming of naive T cells, we performed the ELISpot assay using PBMCs of naive healthy volunteers who had never experienced cutaneous adverse drug reactions. We stimulated the PBMCs of healthy volunteers ($n = 4$) with amoxicillin, one of the causative drugs in our study, and restimulated them after 5 days. In ELISpot data we were unable to detect drug-specific T cells, even on restimulation (see Fig E1 in this article's Online Repository at www.jacionline.org). Either a breakdown product or a drug metabolite might be the drug form that is responsible for drug reactions that are presumed to be immunologic in nature. On the other hand, in our experiments the addition of native drugs to PBMCs induced the activation of drug-specific lymphocytes, indicating that a breakdown product of the drug might be recognized as an antigen *in vitro*. These data reconfirm that even after resolution of SJS/TEN, drug-specific lymphocytes still circulate, as previously reported.¹⁸

We used NOG mice, which lack T cells, B cells, and natural killer (NK) cells, as immunocompromised mice.¹⁹ NOG mice are characterized by tolerance to human cells, which enables humanized mice to be established.²⁰ However, when human cells are applied to NOG mice, GVHRs can occur because engrafted human immune cells attack mouse tissues.²¹ The NOG mice showed GVHD symptoms at 46.3 ± 14.3 days after intravenous transplantation of 2.5×10^6 PBMCs.²¹ Indeed, at 40 days after human PBMCs were injected intravenously into the NOG mice, weight loss, skin erosion, and diarrhea were noticed as symptoms of GVHRs in our experiments. The skin lesions of patients with GVHRs were quite similar to those of patients with SJS/TEN. Skin erosion and hair loss were observed clinically, and epithelial cell death and epidermal detachment were observed histologically. In addition, human CD45⁺ cells were detected in mouse peripheral blood at 20 days after PBMC injection (see Fig E2 in this article's Online Repository at www.jacionline.org), showing that activation of injected human cells had occurred in the NOG mice.




FIG 2. PBMCs from patients with SJS/TEN and causative drug-induced ocular manifestations similar to those of SJS/TEN in NOG mice. **A and B,** At 12 days after PBMC injection and causative drug intake, significant conjunctival congestion and conjunctival chemosis are noticed. The PBMC-injected mice without causative drug intake showed no such symptoms. Histologic analysis showed marked edema of the conjunctival subepithelia in the SJS/TEN-PBMC⁺drug⁺ mice. The TUNEL assay detected numerous dead epithelial cells in the SJS/TEN-PBMC⁺drug⁺ mice (78% of cells) but not in the SJS/TEN-PBMC⁺drug⁻ mice (5% of cells). There was no increase in keratinocyte death in the skin in either group. **HE,** Hematoxylin and eosin. **C,** Human IFN- γ ELISpot with mice splenocytes was performed to confirm that causative drug-specific immune reaction occurred in those mice. At 12 days after PBMC injection, the number of causative drug-specific lymphocytes in the SJS/TEN-PBMC⁺drug⁺ mice was significantly increased compared with that of the SJS/TEN-PBMC⁺drug⁻ mice. Samples from patients 1, 2, 4, and 5 with SJS/TEN and patient 1 with an ODSR were used, and representative data (patient 2) are shown.

In contrast, within 20 days after PBMC injection, no GVHR symptoms appeared (n = 5). Therefore to distinguish clearly between GVHRs and SJS/TEN reactions, we examined mouse model experiments up to 14 days after PBMC administration.

At 12 days after PBMC injection and causative drug intake, marked conjunctival congestion and conjunctival chemosis were noticed, whereas PBMC-injected mice without causative drug intake showed no such symptoms (Fig 2, A). Histologic analysis showed marked edema of the conjunctival subepithelia and vasodilatation in mice receiving PBMCs and causative drug administration (SJS/TEN-PBMC⁺drug⁺ mice). We made 20 model mice, all of which showed similar manifestations. Furthermore, the TUNEL assay found numerous dead epithelial cells in the SJS/TEN-PBMC⁺drug⁺ mice (78% of cells; Fig 2, B) but not in the PBMC-injected, non-drug-administered (SJS/TEN-PBMC⁺drug⁻) mice (5% of cells). Unexpectedly, there were no skin manifestations in either group and no difference in percentages of dead keratinocytes between the groups. At 40 days after PBMC injection, weight loss, skin erosion, hair loss, and diarrhea were noticed. Prominent epithelial cell death was observed histologically (see Fig E3 in this article's Online Repository at www.jacionline.org). These data were virtually identical to those of the GVHD model.

To analyze the occurrence mechanism of SJS/TEN in the model mice, we investigated various conditions that might elicit ocular manifestations similar to those of patients with SJS/TEN (Table I). We observed conjunctival congestion and conjunctival chemosis in our model mice.

TABLE I. Occurrence of ocular manifestations in NOG mice in various conditions

Injected cells	Causative drug intake	Ocular manifestations
PBMCs from patients with SJS/TEN	+	+ (Day 12)
PBMCs from patients with SJS/TEN	-	-
Restimulated PBMCs from patients with SJS/TEN	+	+ (Day 6)
PBMC-depleted CD4 ⁺ cells from patients with TEN	+	+ (Day 14)
PBMC-depleted CD4 ⁺ cells from patients with TEN	+	-
PBMCs from patients with ODSRs	+	-
PBMCs from patients with ODSRs	-	-
Healthy control PBMCs	+	-
Healthy control PBMCs	-	-
None	+	-

Samples from patients 1 and 2 with SJS/TEN and patient 1 with an ODSR were analyzed, and representative data (patient 2 with SJS/TEN and patient 1 with an ODSR) are shown.

Causative drug intake alone did not induce ocular manifestations in the NOG mice. Healthy control PBMCs and acetaminophen, amoxicillin, or phenytoin, which were the causative drugs in the patients with SJS/TEN described in this article, also did not induce ocular manifestations. Importantly, PBMCs from patients who recovered from ODSRs (ie, nonsevere drug-induced skin reactions) and causative drug intake did not elicit ocular

manifestations. However, we were able to find drug-specific T cells in the spleens of NOG mice after ODSR PBMC transfer and orally administered causative drug by using the same ELISpot assay (see Fig E4 in this article's Online Repository at www.jacionline.org). These data showed the ocular manifestations to be a phenomenon specific to PBMCs from patients with SJS/TEN. In addition, causative drug–restimulated PBMCs from patients with SJS/TEN accelerated the onset of ocular manifestations. CD4⁺ or CD8⁺ T lymphocytes were depleted from the PBMCs to identify which lymphocyte subtype is critical in inducing ocular manifestations. CD4⁺ T lymphocyte–depleted PBMCs from patients with SJS/TEN were able to induce ocular manifestations, whereas CD8⁺ T lymphocyte–depleted PBMCs from patients with SJS/TEN were not (see Fig E5 in this article's Online Repository at www.jacionline.org).

These data demonstrate that we have succeeded in establishing model mice showing ocular manifestations (ie, SJS/TEN model mice). In addition, the ocular manifestations similar to those of patients with SJS/TEN in NOG mice were found to be dependent on the causative drug–specific lymphocytes of patients with SJS/TEN, and CD8⁺ T cells are essential to this phenomenon.

Soluble factors, such as granulysin, were not mediators of conjunctival cell death in the SJS/TEN mouse model

In our novel SJS/TEN mouse model, there were almost no infiltrating human cells (human CD45⁺ cells) in the conjunctiva, whereas numerous human cells were detected in the conjunctiva of the mice with GVHRs (see Fig E6 in this article's Online Repository at www.jacionline.org). Therefore it might be that conjunctival cell death is partially induced by soluble factors in addition to direct lymphocyte–epithelium interaction. As mentioned above, we and others have shown that granulysin might contribute to SJS/TEN occurrence. We examined granulysin levels in the supernatants of causative drug–stimulated PBMCs. Causative drug–stimulated PBMCs from patients with SJS/TEN secreted granulysin at levels less than (0.2 ± 0.3 ng/mL) than the serum levels of patients with acute-phase SJS/TEN (24.8 ± 21.2 ng/mL) and those of healthy control subjects (1.6 ± 0.6 ng/mL).¹¹ In addition, granulysin immunohistostaining in the conjunctiva of SJS/TEN model mice and in grafted skin from patients with SJS-TEN showed almost no granulysin expression in these tissues (data not shown). Furthermore, human granulysin and sFasL levels in the sera of mice were measured at days 8 and 12. Serum levels of human granulysin and sFasL were undetectable at these time points. Although ELISA for murine granulysin was not available, we measured murine sFasL levels in these samples. We did not detect an increase in murine sFasL levels in sera from SJS/TEN model mice (data not shown). Therefore granulysin was unlikely to be a candidate for mediating conjunctival cell death in SJS/TEN in our model mice.

Development of an SJS/TEN mouse model using PBMCs and the skin of patients who had recovered from SJS/TEN

In our novel SJS/TEN mouse model skin manifestations did not appear; these model mice do not mimic human SJS/TEN

completely because the target epithelium was murine in origin. We tried to generate another mouse model to simulate skin manifestations.

First, skin from a patient who had recovered from SJS/TEN was grafted onto the backs of NOG mice. After engraftment was confirmed, PBMCs from the same patient were administered intravenously, followed by oral administration of the causative drug (Fig 3, A). In this model both the effector cells and the target cells originate from the same patient with SJS/TEN.

Darkening appeared in the skin graft at 4 days after PBMC injection (Fig 3, B). The darkened area increased at 8 days after PBMC injection (Fig 3, C). In contrast, we observed no color changes and histologic findings showed few keratinocyte deaths in skin-grafted areas at 8 days after PBMC injection without causative drug intake (see Fig E7 in this article's Online Repository at www.jacionline.org). With PBMCs and skin from the same healthy control subject, no necrotic area appeared. Detection of caspase-3 proves that apoptosis has occurred because it is either partially or totally responsible for the proteolytic cleavage of many key proteins, such as the nuclear enzyme poly (ADPribose) polymerase. Using cleaved caspase-3 staining, we confirmed the increase in keratinocyte death in the SJS/TEN skin graft compared with that seen in the healthy control animals (Fig 3, D). In addition, we transplanted skin from patients with ODSRs onto NOG mice and injected the same patients' PBMCs, followed by administration of the causative drug or the vehicle. These mice showed no changes in the appearance of the skin-grafted areas. Histopathologically, the number of apoptotic keratinocytes in ODSR model mice did not differ between the causative drug group and the vehicle group (see Fig E8 in this article's Online Repository at www.jacionline.org).

To investigate the infiltrated cell types, we performed skin graft staining. Both human CD4⁺ and CD8⁺ T cells were infiltrated in the transplanted skin areas. However, there were no differences in the numbers of cells between the patient with SJS/TEN and the control (Fig 4). These findings indicate that infiltrating lymphocytes are not critical in this model. The manifestations of these models were quite similar to those in skin lesions of patients with SJS/TEN.

DISCUSSION

The present study aimed to develop a mouse model to mimic human SJS/TEN. We succeeded in reproducing SJS/TEN-like manifestations in the mice. Our results provide an SJS/TEN animal model that promises to be useful in experiments involving SJS/TEN.

To date, investigations to reveal the pathomechanism of SJS/TEN have been carried out with human samples. In previous reports reactions in the acute phase of SJS/TEN in peripheral blood and skin lesions were analyzed, and these investigations have shown that inflammatory mediators, proapoptotic mediators, or infiltrated cells in the skin lesions might be linked to the occurrence of SJS/TEN.

Chung et al¹⁰ attempted to identify key molecules in skin lesions (bullae), and they focused on the most highly expressed proapoptotic molecule: granulysin. Granulysin was found to induce cultured keratinocyte death. Furthermore, recombinant granulysin injection into the murine skin elicited skin necrosis. In addition, we detected higher concentrations of serum granulysin in the acute phase of SJS/TEN than in ODSRs.¹¹ In contrast,




FIG 3. Development of the SJS/TEN mouse model using PBMCs and skin grafts of patients who had recovered from SJS/TEN. **A**, Scheme of mouse model development. Skin grafts from a patient who had recovered from SJS/TEN were grafted onto the backs of NOG mice. After engraftment was confirmed, PBMCs from the same patient were applied intravenously, followed by oral administration of the causative drug. **B** and **C**, Darkened areas appear in the skin graft at 4 days after PBMC injection. These areas were increased at 8 days after PBMC injection. In contrast, the darkened area did not appear in skin grafts of mice when using PBMCs and skin from the healthy control subject. **D**, By using cleaved caspase-3 staining, a great increase in keratinocyte death in the SJS/TEN skin graft was detected in comparison with the keratinocyte death seen in the healthy control specimens. Samples from patient 6 with SJS/TEN and patient 2 with an ODSR were used. *i.v.*, Intravenous; *p.o.*, by mouth.




FIG 4. Human CD4 and CD8 staining was performed. Both human CD4⁺ and CD8⁺ T cells infiltrated the transplanted skin areas. There were no differences in the numbers of cells between patients with SJS/TEN and controls. Samples from patient 6 with SJS/TEN were used. *HPF*, High-powered field; *N.S.*, not significant.

French's group reported that Fas and Fas ligand interaction is critical in SJS/TEN pathogenesis.⁷ They reported that keratinocyte apoptosis in patients with SJS/TEN is mediated by Fas and Fas ligand, which are both expressed on keratinocytes. We also reported that sFasL was able to induce keratinocyte death⁸ and that the serum level of sFasL was increased in the acute phase of SJS/TEN, as was the serum level of granulysin.²² Other candidates, such as α -defensin, have also been reported.²³

A recent article reported that NK-cytolytic T lymphocyte (CTLs) might be a cell component that contributes to SJS/TEN occurrence. Activated CTLs gain NK cell-like function; these are called NK-CTLs, and they specifically express CD94/NKG2C. NK-CTLs accumulate in skin lesions of patients with SJS/TEN, where they induce keratinocyte death through an interaction between CD94/NKG2C and HLA-E that is expressed specifically on keratinocytes of SJS/TEN lesions.²⁴

Even though knowledge regarding the mechanism of SJS/TEN has been accumulated, these findings have never been confirmed in an *in vivo* model. If some molecules were highly expressed in skin lesions or blood during the acute phase of SJS/TEN, there would be no way to confirm whether these molecules are key players. Regarding proapoptotic molecules, several candidates have been reported, as described above. However, most reports focused on molecules that researchers anticipated to contribute to SJS/TEN pathogenesis. Granulysin was identified by means of DNA microarray of cells in bullae; however, not only did the data show that the mRNA level of granulysin was increased, they also showed that the mRNA levels of other proapoptotic molecules, such as Fas ligand, perforin, and granzyme B, were increased.¹⁰ This suggests that several pathways are activated in the apoptotic phenomenon *in vivo*, and there is no solid evidence of an exclusive key player. Animal model experiments involving

depletion or inhibition of specific molecules were essential in proving their uniqueness. Previous experiments with patients' specimens provided fragmentary information on disease etiology. Our model mice open the possibility of recreating the pathologic conditions of SJS/TEN in mice and conducting circumstantial *in vivo* examinations, such as on the benefits of treatments. In our study CD8⁺ lymphocyte-depleted PBMCs did not produce SJS-like symptoms, strongly demonstrating that CD8⁺ lymphocytes are necessary to SJS/TEN pathogenesis. Previous reports showed that CD4⁺ T cells were the predominant population that infiltrated into "maculopapular rash" skin lesions and that most drug-specific T cells were CD4⁺ T cells.²⁵ However, in severe cutaneous adverse drug reactions CD8⁺ T cells were the predominant population that infiltrated into the epidermis of skin lesions of patients with SJS/TEN,¹⁰ and HLA-B*1502 was found to be associated with carbamazepine-induced SJS in all cases.²⁶ In addition, drug-specific CD8⁺ T cells were found to predominantly proliferate during the acute stages of SJS.²⁷ Although drug-specific CD4⁺ T cells are essential in drug-mediated immune reactions, CD8⁺ T cells are critical to the development of SJS/TEN. Furthermore, in the skin lesions of model mice, the numbers of CD4⁺ and CD8⁺ lymphocytes did not differ between patients with SJS/TEN and control subjects. These findings indicate that infiltrating lymphocytes are not required to generate SJS/TEN skin lesions. Given the findings of ocular lesions, we made the supposition that soluble factors might be involved in keratinocyte death. Although granulysin and sFasL were not specific mediators of this phenomenon, we speculated that causative drug-stimulated PBMCs from patients with SJS/TEN secreted certain cell-death mediators.

Our data using this model also suggest that drug presentation and recognition in the skin might be less necessary than expected because some symptoms develop with little or no recruitment of drug-specific T cells. In our model mice it seems that drug-specific cells were presented and activated by APCs at the spleen and not the skin. Therefore we consider that human APCs presented drug/antigen to T cells in the spleen or peripheral blood. Taken together, we conclude that soluble factors from CD8⁺ lymphocytes are critical for SJS/TEN development. Our model mice are useful experimental tools to reveal the SJS/TEN pathomechanism.

It is possible that PBMCs from patients with SJS/TEN, which are activated by the causative drug, are highly proliferative and lead to human PBMC reconstitution at day 12, resulting in accelerated GVHRs. However, GVHRs are mediated by human cell infiltration into murine tissue. Indeed, in the GVHR model we detected numerous human cells in the conjunctiva of the mice, whereas in the SJS/TEN-PBMC model, we detected few human cells in conjunctiva and peripheral blood at day 12. These data indicated that at least the ocular manifestations of mice receiving SJS/TEN-PBMC/drug at day 12 were not GVHRs. If PBMCs are highly proliferative at day 12, ocular manifestations can be regarded as a drug-specific phenomenon because mice receiving only PBMCs from patients with SJS/TEN never show such symptoms.

In our model mice it is speculated that the APCs of mice presented drug/antigens to human drug-specific lymphocytes. However the NOG mice used in our experiments have no T, B, and NK cells. In addition, the dendritic cells (DCs) of NOG mice are deficient in antigen presentation.¹⁹ Indeed, dysfunction of DCs allowed engraftment by human cells in NOG mice (ie, DCs of NOG

were unable to present xenoantigen to human lymphocytes sufficiently). Therefore we assume that donor human APCs present drug antigens to T cells. Furthermore, by using human IFN- γ ELISpot, the number of drug-specific lymphocytes increased in the spleens of the SJS/TEN-PBMC model mice.

From the clinical aspect, issues have included the difficulty of early diagnosis of SJS/TEN and unresponsiveness to treatment. In the early stage SJS/TEN presents clinically as edematous papules or erythema multiforme-like target rashes that are very similar to those of ODSRs. Such a clinical course makes it difficult to reach a diagnosis of SJS/TEN in the early stage, which results in high mortality rates. Furthermore, the majority of SJS/TEN cases progress rapidly within a few days; therefore methods of early diagnosis are urgently required. We previously analyzed serum samples from 5 patients with SJS/TEN in the early stage (before skin erosions or mucous lesions appeared) and showed that serum levels of sFasL and granulysin are predictors of SJS/TEN diagnosis.^{11,22} However, collecting samples at the early stage was quite difficult because of the rarity of the diseases and the intractability of the diagnosis in the early stage, as mentioned above. The present mouse model might allow assessment of changes over time and provide other predictors of early diagnosis and severity of SJS/TEN. Furthermore, treatment interventions are able to be implemented in the early phase in our model, contributing to the prediction of disease onset and prognosis.

We thank Ms Ayumi Moriya for her technical expertise.

Clinical implications: We report a novel mouse model of SJS/TEN that was developed by using PBMCs and skin from patients who had recovered from SJS/TEN. The model promises to promote diagnostic and therapeutic approaches.

REFERENCES

- Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *N Engl J Med* 1995;333:1600-7.
- Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. *Arch Dermatol* 1993;129:92-6.
- Di Pascuale MA, Espana EM, Liu DT, Kawakita T, Li W, Gao YY, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. *Ophthalmology* 2005;112:904-12.
- Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. *J Am Acad Dermatol* 2007;56:181-200.
- Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. *J Am Acad Dermatol* 2008;58:33-40.
- Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrolysis. *J Dermatol Sci* 2012;66:190-6.
- Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. *Science* 1998;282:490-3.
- Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. *Am J Pathol* 2003;162:1515-20.
- Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. *J Allergy Clin Immunol* 2002;109:155-61.
- Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Nat Med* 2008;14:1343-50.

11. Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. *Ann Intern Med* 2009;151:514-5.
12. Lee JY, Chae DW, Kim SM, Nam ES, Jang MK, Lee JH, et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. *J Viral Hepat* 2004;11:130-5.
13. Das H, Imoto S, Murayama T, Kajimoto K, Sugimoto T, Isobe T, et al. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. *Br J Haematol* 1999;104:795-800.
14. Azukizawa H, Kosaka H, Sano S, Heath WR, Takahashi I, Gao XH, et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. *Eur J Immunol* 2003;33:1879-88.
15. Azukizawa H, Sano S, Kosaka H, Sumikawa Y, Itami S. Prevention of toxic epidermal necrolysis by regulatory T cells. *Eur J Immunol* 2005;35:1722-30.
16. Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. *J Virol* 2005;79:2087-96.
17. Beeler A, Engler O, Gerber BO, Pichler WJ. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. *J Allergy Clin Immunol* 2006;117:455-62.
18. Rozieres A, Hennino A, Rodet K, Gutowski MC, Gunera-Saad N, Berard F, et al. Detection and quantification of drug-specific T cells in penicillin allergy. *Allergy* 2009;64:534-42.
19. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. *Blood* 2002;100:3175-82.
20. Ito M, Kobayashi K, Nakahata T. NOD/Shi-scld IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. *Curr Top Microbiol Immunol* 2008;324:53-76.
21. Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. *Transplantation* 2009;87:1654-8.
22. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. *J Allergy Clin Immunol* 2008;122:992-1000.
23. Morel E, Alvarez L, Cabanas R, Fiandor A, Diaz R, Escamochero S, et al. Expression of alpha-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions. *Allergy* 2011;66:360-7.
24. Morel E, Escamochero S, Cabanas R, Diaz R, Fiandor A, Bellon T. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. *J Allergy Clin Immunol* 2010;125:703-10, e1-10.
25. Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B, et al. T cell involvement in cutaneous drug eruptions. *Clin Exp Allergy* 2001;31:1398-408.
26. Chung WH, Hung SI, Hong HS, Hsieh MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature* 2004;428:486.
27. Hanafusa T, Azukizawa H, Matsumura S, Katayama I. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity. *J Dermatol Sci* 2012;65:213-9.




FIG E1. ELISpot assays with PBMCs of naive healthy volunteers who had never experienced cutaneous adverse drug reaction were performed. PBMCs of healthy volunteers ($n = 4$) were stimulated with amoxicillin, one of the causative drugs in our study, and restimulated after 5 days. ELISpot analysis did not detect drug-specific T cells, even in restimulation. *D+*, Drug addition; *D-*, no drug addition.